Penumbra Inc (PEN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Penumbra Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 321.20 $ — 72% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
8 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 18.3% passed
- More than 10% revenue growth is expected for the coming year 12.6% passed
- Share count grows by less than 3% a year 1.3% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 30.0% failed
- Gross margin at 40% or higher and without meaningful erosion 67.1% passed
- Goodwill from acquisitions does not grow faster than revenue 9.1% passed
- Net debt below twice EBITDA 0.2 x EBITDA passed
- Operating cash flow covers the profits of the last three years 222 m passed
- Return on capital at 15% or higher, or up versus two years ago 11.5% passed
- Insiders hold at least 10% or are net buyers 2.9% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 12.6% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 18
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4.75 | 4.64 – 4.85 | 1,596 | 23.6% | 5 |
| 12/31/2027 | 6.20 | 5.12 – 7.06 | 1,802 | 30.7% | 13 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.86 | -37.80 | 316 | 10.80 | 10.70 | 51 | 46 |
| 2025: Q1 | 1.00 | 258.50 | 324 | 16.30 | 12.10 | 49 | 36 |
| 2025: Q2 | 1.15 | – | 340 | 13.40 | 13.30 | 45 | 29 |
| 2025: Q3 | 1.17 | 54.80 | 355 | 17.80 | 12.90 | 58 | 42 |
| 2025: Q4 | 1.20 | 40.10 | 385 | 22.10 | 12.30 | 87 | 68 |
| 2026: Q1 | 0.82 | -17.70 | 375 | 15.60 | 8.70 | 87 | 73 |
| 2026: Q2 | 0.88 | -23.50 | 390 | 14.90 | 8.90 | 46 | 33 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 263 | -1 | 15 | 0.44 | -13 | 267 | 308 |
| 2017 | 334 | 1 | 5 | 0.13 | 13 | 400 | 477 |
| 2018 | 445 | -1 | 7 | 0.18 | 29 | 422 | 515 |
| 2019 | 547 | 48 | 48 | 1.34 | 27 | 486 | 666 |
| 2020 | 560 | -39 | -19 | -0.54 | -33 | 642 | 823 |
| 2021 | 748 | -8 | 3 | 0.07 | 10 | 954 | 1,244 |
| 2022 | 847 | 6 | -2 | -0.05 | -56 | 999 | 1,371 |
| 2023 | 1,059 | 74 | 91 | 2.32 | 97 | 1,179 | 1,556 |
| 2024 | 1,195 | 86 | 14 | 0.36 | 168 | 1,151 | 1,533 |
| 2025 | 1,404 | 189 | 178 | 4.52 | 239 | 1,428 | 1,827 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Penumbra, Inc. entwirft, entwickelt, fertigt und vermarktet mit ihren Tochtergesellschaften Medizinprodukte in den USA und international.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 4,700 |
| Headquarters | Alameda, CA |
| Address | One Penumbra Place, 94502 Alameda, United States |
| Phone | 510 748 3200 |
| Website | penumbrainc.com |
| IPO Date | 18. Sep 2015 |
| ISIN | US70975L1070 |
| Stock Split | 1:10 on 11/16/2014 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Adam Elsesser J.D. | Co-Founder, Chairman & CEO | 1962 |
| Shruthi Narayan | President | 1985 |
| Arani Bose M.D. | Co-Founder & Director | 1962 |
| Maggie S. Yuen | Chief Financial Officer | 1972 |
| Lambert Shiu | Chief Accounting Officer | 1980 |
| Johanna Roberts J.D. | Executive VP, General Counsel & Secretary | 1972 |
| Ben Sorci | Executive Vice President of Operations | – |
| Pankaj Tiwari | Executive VP & Chief Information Officer | – |
| Jee Hamlyn-Harris | Investor Relations Officer | – |
| Ben Tompkins | Executive Vice President of Development & Compliance | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.